RE:RE:RE:Where is the insider buying???Apart from low insider ownership the other issue with THTX is that insiders act long outsiders and outsiders do insiders' Job. We "outsiders" have explored/analaysed and advertised publicly (on this MB
and elsewhere) all the prospects of company's operations repeatedly! From the R&D to commercial drugs, from the scientific to financial opportunities. So we have done a good job of convincing ourselves and folks who follow the board there is a valid investment thesis for this company, there are many opportunities when and if materialized each and every of them can make this investment very rewarding. Well this is the job for insiders so many more outsiders/investors get the message yet the insiders have chosen to not to...The high risk high reward scenario comes across as high risk questionable high reward, that's the general perception in my opinion. They have failed to highlight/communicate the reward part of the equation to the capital market and everyone knows the risks involved. As mentioned earlier folks invest in preclinical companies with no commercial operations but the interest in THTX is nothing close to what it should be. Buying shares is a good start but they need to realize the importance of an effective marketing so this high risk high reward investment get the attention it deserves specifically the reward part. Many exciting shareholders feel lost as it seems all the achievements won't move the valuation and not many new investors are happy to enter THTX's wonderland.